Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (DE:DUL)
FRANKFURT:DUL
DUL Analyst Ratings
Strong Buy
15 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DUL Stock 12 Month Forecast
Average Price Target
€303.80
▲(33.36% Upside)
| Highest Price Target€460.49 | Average Price Target€303.80 | Lowest Price Target€261.56 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
Reiterated
03/03/25
TD Cowen
Reiterated
02/26/25
William Blair
Reiterated
02/26/25
Barclays
Reiterated
02/26/25
Stifel Nicolaus
Reiterated
02/26/25
Canaccord Genuity
Reiterated
02/26/25
Needham
Reiterated
02/26/25
Morgan Stanley
Reiterated
02/26/25
Piper Sandler
Reiterated
02/26/25
Bank of America Securities
Reiterated
02/25/25
BMO Capital
€278.06
Buy
22.06%
Upside
Reiterated
02/25/25
Alnylam Pharma's Strategic Advancements and Promising Pipeline Drive Buy Rating
Leerink Partners
―
Hold
―
Reiterated
02/25/25
Alnylam Pharmaceuticals: Balancing Promising Pipeline with Competitive Challenges and Strategic Uncertainties
RBC Capital
€278.06→€287.33
Buy
26.13%
Upside
Reiterated
02/25/25
Alnylam Pharma (ALNY) Receives a Buy from RBC Capital
Bernstein
€287.33→€282.69
Buy
24.10%
Upside
Reiterated
02/14/25
Alnylam Pharmaceuticals (ALNY) PT Lowered to $305 at Bernstein SocGen GroupBernstein SocGen Group analyst William Pickering lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $305.00 (from $310.00) while maintaining a Outperform rating.
Scotiabank
€287.33→€278.06
Buy
22.06%
Upside
Reiterated
02/14/25
Scotiabank Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
03/03/25
TD Cowen
Reiterated
02/26/25
William Blair
Reiterated
02/26/25
Barclays
Reiterated
02/26/25
Stifel Nicolaus
Reiterated
02/26/25
Canaccord Genuity
Reiterated
02/26/25
Needham
Reiterated
02/26/25
Morgan Stanley
Reiterated
02/26/25
Piper Sandler
Reiterated
02/26/25
Bank of America Securities
Reiterated
02/25/25
BMO Capital
€278.06
Buy
22.06%
Upside
Reiterated
02/25/25
Alnylam Pharma's Strategic Advancements and Promising Pipeline Drive Buy Rating
Leerink Partners
―
Hold
―
Reiterated
02/25/25
Alnylam Pharmaceuticals: Balancing Promising Pipeline with Competitive Challenges and Strategic Uncertainties
RBC Capital
€278.06→€287.33
Buy
26.13%
Upside
Reiterated
02/25/25
Alnylam Pharma (ALNY) Receives a Buy from RBC Capital
Bernstein
€287.33→€282.69
Buy
24.10%
Upside
Reiterated
02/14/25
Alnylam Pharmaceuticals (ALNY) PT Lowered to $305 at Bernstein SocGen GroupBernstein SocGen Group analyst William Pickering lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $305.00 (from $310.00) while maintaining a Outperform rating.
Scotiabank
€287.33→€278.06
Buy
22.06%
Upside
Reiterated
02/14/25
Scotiabank Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Best Analysts Covering Alnylam Pharma
Which Analyst Should I Follow If I Want to Buy DE:DUL and Sell After:
1 Month
xxx
Success Rate
14/24 ratings generated profit
Average Return
+0.54%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +0.54% per trade.
3 Months
xxx
Success Rate
22/37 ratings generated profit
Average Return
+4.26%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 59.46% of your transactions generating a profit, with an average return of +4.26% per trade.
1 Year
Success Rate
26/37 ratings generated profit
Average Return
+26.03%
reiterated a buy rating 4 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 72.97% of your transactions generating a profit, with an average return of +26.03% per trade.
2 Years
xxx
Success Rate
33/37 ratings generated profit
Average Return
+40.12%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 89.19% of your transactions generating a profit, with an average return of +40.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DUL Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
5
4
5
6
7
Buy
50
36
22
27
25
Hold
14
13
8
6
5
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
70
54
36
39
37
Each month's total comprises the sum of three months' worth of ratings.
DUL Financial Forecast
DUL Stock Forecast FAQ
What is DE:DUL’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is €303.80.
What is DE:DUL’s upside potential, based on the analysts’ average price target?
Alnylam Pharmaceuticals has 33.36% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 15 buy ratings, 3 hold ratings and 0 sell ratings.
What is Alnylam Pharmaceuticals’s share price target?
The average share price target for Alnylam Pharmaceuticals is €303.80. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €460.49 ,and the lowest forecast is €261.56. The average share price target represents 33.36% Increase from the current price of €227.8.
The highest analyst share price target is €460.49 ,and the lowest forecast is €261.56. The average share price target represents 33.36% Increase from the current price of €227.8.
What do analysts say about Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of Alnylam Pharmaceuticals?
To buy shares of DE:DUL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.